Clinical Trial

The African-PREDICT Study

Study acronym: PREDICT
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The African-PREDICT study aims to (i) generate new knowledge on the early pathophysiology accompanying hypertension development in black South Africans; and (ii) to identify early novel markers or predictors for the development of hypertension and cardiovascular outcome. By employing also in Africa the latest cutting-edge scientific technologies to measure single and multiple biomarkers proven to predict hypertension and cardiovascular outcome (such as multiplex analyses, proteomics and metabolomics), precision medicine may have the potential to lead to novel strategies in preventing and treating hypertension in Africa.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-09-22; most recent amendment 2024-04-24.
Status change: Recruiting → Active, Not Recruiting 2018-08-07
Trial Details
NCT Number NCT03292094
Lead Sponsor North-West University, South Africa
Collaborators: Medical Research Council, South Africa, National Research Foundation of South Africa, GlaxoSmithKline, Medical Research Council, Pfizer, Boehringer Ingelheim, Novartis, Mediclinic Hospital, Roche Diagnostics GmbH
Conditions Cardiovascular Diseases, Hypertension, Health Risk Behaviors, Arterial Stiffness, Young, Renin Hypertension
Enrollment 1,202 participants
Start Date 2013-02-04
Primary Completion 2017-11-30 (estimated)
Study Completion 2027-12-03 (estimated)
Updated on ClinicalTrials.gov 2024-04-25